ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS Registered as Stocks Under $5 Gain Attention Inside

As metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH move toward large-scale clinical adoption, ENDRA Life Sciences (NASDAQ: NDRA) is emerging as a key player in solving one of the industry's biggest challenges: scalable liver imaging.

The rapid expansion of GLP-1 therapies and large global trials-such as Eli Lilly's multi-thousand patient studies-are highlighting a critical issue: current diagnostic tools cannot scale efficiently. The gold standard, MRI-PDFF, delivers precision but costs $2,000-$3,000 per scan, creating tens of millions in imaging costs per trial and limiting widespread use.

ENDRA's TAEUS Registered (Thermo-Acoustic Enhanced UltraSound) technology is designed to change that dynamic. By enabling non-invasive liver fat measurement at the point of care, TAEUS aims to deliver comparable insights at approximately $100 per scan, representing up to a 90%+ cost reduction.

Beyond cost savings, TAEUS could enable broader patient screening, faster trial enrollment, and more frequent monitoring, helping scale MASLD and MASH treatment programs globally.

Stocks Under $5 With Upside Potential Gain Investor Attention

As investors search for high-upside small-cap opportunities, several stocks under $5 are gaining traction across healthcare, energy, and emerging technology sectors.

Alongside ENDRA Life Sciences (NASDAQ: NDRA), other names drawing attention include Advanced Biomed Inc (NASDAQ: ADVB), Sky Quarry Inc (NASDAQ: SKYQ), Kiora Pharmaceuticals Inc (NASDAQ: KPRX) and Battalion Oil Corp (NASDAQ: BATL).

These companies represent a mix of innovative healthcare solutions, resource development, and energy exposure, offering investors diversified entry points into emerging growth themes. In particular, NDRA stands out within this group as a pure-play diagnostic infrastructure company tied to the rapidly expanding MASLD and GLP-1 healthcare markets.

The Bottom Line

As pharmaceutical investment accelerates and demand for affordable liver diagnostics grows, ENDRA is positioning itself not just as a device company-but as a potential infrastructure layer for the future of liver disease management.

With macro tailwinds from MASH therapies, GLP-1 adoption, and rising global liver disease prevalence, companies enabling scalable diagnostics could play a critical role in the next phase of healthcare expansion.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endra-life-sciences-nasdaq-ndra-targets-masld-and-glp1-imaging-bottleneck-with-taeus-as-stocks-under-5-gain-attention-inside]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.